H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on EDAP TMS to $10 from $14 and keeps a Buy rating on the shares. The firm says the company exited fiscal 2025 with two major milestones - establishing high-intensity focused ultrasound as its core business segment and becoming a U.S. domestic filer.
